Status:
COMPLETED
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Conditions:
Hepatitis C Virus Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This is a follow-up study with no treatment and only samples being collected.
Detailed Description
The purpose of this study is to evaluate the development of specific viral mutations in response to treatment with ABT-072.
Eligibility Criteria
Inclusion
- \- Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior study involving ABT-072.
Exclusion
- \- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in a prior ABT-072 clinical study.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00872196
Start Date
April 1 2009
End Date
April 1 2010
Last Update
April 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 18222
Los Angeles, California, United States, 90036